Twenty-seven percent of 50 heavily pretreated patients with stage IV HER2+ breast cancer saw clinical benefit from the drug Tucatinib (ONT-380) , with at least ‘stable disease’ at 24 or more weeks after the start of treatment.
Twenty-seven percent of 50 heavily pretreated patients with stage IV HER2+ breast cancer saw clinical benefit from the drug Tucatinib (ONT-380) , with at least ‘stable disease’ at 24 or more weeks after the start of treatment.